RecruitingPhase 3NCT05908084

To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

Studying Complication in hemodialysis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Humacyte, Inc.
Intervention
Acellular Tissue Engineered Vessel (ATEV)(biological)
Enrollment
150 target
Eligibility
18 years · FEMALE
Timeline
20232027

Study locations (30)

Collaborators

IQVIA Biotech

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05908084 on ClinicalTrials.gov

Other trials for Complication in hemodialysis

Additional recruiting or active studies for the same condition.

See all trials for Complication in hemodialysis

← Back to all trials